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The signaling response to DNA damage: ATM and
ATR
One of the most basic and indeed dangerous forms of DNA dam-
age is that of breaks or discontinuities in the double helix. DNA
breakage can result in loss of genetic information or serve as a plat-
form for deleterious translocations which can alter the coding nature
of DNA. Both ATM (Ataxia Telangiectasia Mutated) and ATR
(Ataxia Telangiectasia and Rad3-related) are protein kinases of the
phosphoinositol 3-kinase-like kinase (PI3KK) family that play a key
role in coordinating the signal transduction response to these types
of DNA damage.1 Both kinases phosphorylate many of the same
substrates (e.g. Brca1, p53) and collectively activate similar signal
transduction pathways encompassing many proteins that function in
DNA damage sensing, mediator and transducer proteins that trans-
mit and amplify this signal and ultimately effector proteins that carry
out the particular responses including cell cycle checkpoint activation
or apoptosis induction. Specifically in the case of ATM, a role in the
actual repair of DNA double strand breaks (DSB's), particularly in
heterochromatinized regions of the genome has also been demon-
strated.2 A large-scale proteomics screen by Matsuoka and colleagues
has identified over 700 proteins phosphorylated by ATM and ATR in
response to DNA damage.3 A similar study by Stokes et al has shed
further light on the amount and diversity of proteins phosphorylated
by these kinases.4 ATM is activated by DSB's whilst ATR is activated
by single stranded regions of DNA which can occur, for example,
during the processing of certain lesions in DNA or during stalling of
DNA replication forks (Figure 1). Increasing evidence suggest that
both kinases can function in concert under certain circumstances. For
example, during S-G2 phase of the cell cycle, DSB's can undergo
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A multitude of clinically distinct human disorders exist whose underlying cause is a defect in the response to or repair of DNA damage. The
clinical spectrum of these conditions provides evidence for the role of the DNA damage response (DDR) in mediating diverse processes such
as genomic stability, immune system function and normal human development. Cell lines from these disorders provide a valuable resource to
help dissect the consequences of compromised DDR at the molecular level. Ataxia telangiectasia and Rad3-related (ATR) and Ataxia
telangiectasia Mutated (ATM) are apical protein kinases that play central roles in coordinating the cells response to DNA damage. Whilst ATM
is activated by DNA double strand breaks (DSB's), ATR is activated by single stranded regions of DNA (ssDNA) which can occur, for example,
during DNA replication fork stalling. There is significant functional overlap between these two kinases. In fact, they phosphorylate many of the
same substrates, including p53 and Brca1. Nevertheless, ATR appears to be essential for embryonic development, unlike ATM. Mutations in
ATM result in Ataxia telangiectasia (A-T) a progressive neurological disorder. Interestingly, a hypomorphic mutation in ATR is associated with
Seckel syndrome, a clinically distinct disorder to that of A-T. Seckel syndrome is characterised by profound proportionate growth retardation
with severe microcephaly. Why defects in these two related kinases should result in such distinct human disorders is unclear. Recently, muta-
tions in Pericentrin/Kendrin (PCNT) have also been demonstrated in Seckel syndrome. PCNT encodes a core structural centrosomal protein.
Interestingly, defective PCNT results in impaired ATR-dependent, but not ATM-dependent G2-M cell cycle checkpoint arrest. Using evidence
from murine knockout studies and human cell-based work I will discuss the biological impact of compromised ATR-pathway function with the
aim of trying to understand the link between genotype-phenotype in this context.
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exonucleolytic resection generating single stranded overhangs hence
shifting the emphasis from ATM signaling to that of ATR.5 Conversely,
stalled replication forks with extensive regions of ATR-activating
single stranded DNA can collapse resulting in DSB formation and
consequently ATM activation (Figure 1).
ATM is recruited to DSB's via a sensor complex composed of
Mre11-Rad50-Nbs1 (MRN complex).6 Structural studies suggest that
this 'sensor' complex can tether both ends of the DSB keeping them
in close proximity.7 Biochemical work has also shown that the MRN
complex may function to process these ends to ultimately facilitate
their repair.8 An early detectable response to DSB's is phosphorylation
of the histone H2A variant, H2AX, which can be carried out redun-
dantly by ATM or another PI3KK family member, DNA-PK.9,10
H2AX phosphorylation (termed ã-H2AX) occurs over megabase pair
regions producing discrete, microscopically detectable foci. Formation
of these foci is required for the retention of mediator proteins, in-
cluding 53BP1 and MDC1, which are required for optimal signal
transduction response. The principal effector of ATM is Chk2, a kinase
that plays a role in controlling the activity of the Cdc25 phosphatase
family that are involved in the activation of various Cdk-Cyclin com-
plexes.11 Following DSB-induction, activated ATM phosphorylates and
activates Chk2 which subsequently phosphorylates Cdc25A thereby
targeting it for rapid ubiquitin-mediated degradation. Consequently,
Cdc25A is not available to remove the inhibitory phosphates on
Cdk-Cyclin complexes including Cdk1-Cyclin B and Cdk2-Cyclin
E. Therefore, these complexes remain inactive resulting in cell cycle
arrest, in this case at the G2-M and G1-S/intra-S boundaries re-
spectively. ATM activity can also negatively impact on cell cycle
progression following DNA in other ways. Following DSB forma-
tion ATM can phosphorylate and stabilise p53. One of its main
transcriptional targets is the Cdk-inhibitor p21WAF1/CIP1. Hence active
Cdk-cyclin complexes can be rapidly inhibited in response to DNA
damage.11
ATR exists as a heterodimer with ATRIP (ATR interacting protein)
and is recruited to ssDNA via the Replication Protein A heterotrimer
(RPA1-3) which rapidly coats single stranded DNA when it occurs
within a cell.12-14 TopBP1 appears to be required for optimal ATR
kinase activity.15 The MRN complex, along with the Rad17/Rfc2-5
and Rad9/Rad1/Hus1 complexes, are all recruited to the site of damage
independently of ATR/ATRIP and are also ATR substrates. Retention
of these complexes facilitates ATR's ability to phosphorylate down
stream substrates such as p53. ATR's key effector is the Chk1 kinase,
which coordinates similar and often overlapping signal transduction
processes to that of Chk2. Nevertheless, whilst ATM and ATR con-
trol overlapping DNA damage response pathways, ATR, unlike ATM
appears to be essential for embryonic development and somatic
growth.12,16 Furthermore, mutations in ATM and ATR confer clini-
cally distinct human conditions. Mutations in ATM cause Ataxia
telangiectasia whilst mutation in ATR cause Seckel syndrome (Table 1).
Ataxia telangiectasia
Ataxia telangiectasia (A-T) is a progressive neurological disorder
characterised by progressive ataxia (loss of muscle coordination),
occulomotor apraxia (failure to execute a learned or skilled motor
act, in this case eye coordination), dysarthria (impaired articulation-
speech impediment), isolated immunoglobin deficiencies and lym-
phoma predisposition.17 A-T is the 'classical' cell cycle checkpoint
defective disorder as cells from these patients exhibit defects in G1-S,
intra-S and G2-M cell cycle checkpoints in response to DSB's. In fact,
failure of intra-S phase checkpoint after IR is used as a diagnostic
24
Figure 1. (A)(i). Depiction of an active DNA replication fork. (ii). The right-hand side of this fork is shown here approaching a DNA replication-
stalling lesion (X) such as a chemically modified base. (iii). Upon replication fork stalling at this lesion, fork helicase activity has been shown to
uncouple from the replicative polymerase generating single stranded tracts of DNA, an ATR-activating form of DNA. (iii). Prolonged stalling can
under certain circumstances result in collapse of the replication fork thus generating double stranded DNA ends, an ATM activating form of DNA.
(B)(i). Ionising radiation (IR) directly induces DNA double strand breaks. (ii). These breaks result in ATM activation. (iii). Under certain circum-
stances, these double stranded DNA ends can undergo exonucleolytic resection (denoted by the dashed line) thereby generating an ATR-activating
form of DNA (iv).
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tool for this condition (RDS; Radio-resistant DNA Synthesis). A-T
cells are also defective in the repair of a subset of DSB's.18 Loss of
ATM increases genomic instability particularly in response to DSB's.
In fact, lymphoid cells from A-T patients frequently exhibit a specific
translocation between chromosome 7 and 14 which arise from a fail-
ure to appropriately deal with Recombination Activating Gene (RAG)-
induced DSB's induced at the T cell receptor and immunoglobin gene
loci during V(D)J recombination. ATM knockout mouse models are
viable and recapitulate most of the clinical features of A-T (aside
from overt ataxia), including tumour predisposition. A recent review
on A-T and ATM signalling by Martin Lavin contains a more de-
tailed description of this topic.19
Seckel syndrome
Helmut Seckel first described the syndrome that now bears his
name in a monograph published in 1960 entitled "Bird Headed
Dwarfs. Studies in Developmental Anthropology Including Human
Proportions".20 He defined this disorder on the basis of 13 cases from
the literature and two personally examined individuals. Seckel syn-
drome is clinically characterised by severe intrauterine and post-natal
growth retardation, profound microcephaly, a 'bird-like' facial profile
with receding forehead and chin, 'beak-like' protruding nose, mental
retardation and isolated skeletal abnormalities (e.g. delayed ossifi-
cation, joint laxity and dislocation). Estimation of the frequency of
this disorder is difficult as it has previously been frequently mis- and
over-diagnosed.21,22 Nevertheless, the amount of published literature
on this disorder suggests that this is a rare condition.
Seckel syndrome is an autosomal recessive disorder and several
homozygosity mapping studies indicate that this disorder is geneti-
cally heterogeneous (Table 2). The first reported mapping study on
Seckel syndrome was by Goodship et al who identified a suscepti-
bility locus on chromosome 3q22.1-q24.23 Subsequently other groups
have identified susceptibility loci on chromosome 18 (p11.31-q11.2),
chromosome 14 (q21-q22) and chromosome 21 (q22.3) (Table 2).24-26
The first genetic defect identified in Seckel syndrome was a single
synonomous mutation in ATR (A>G 2101) in two related Pakistani
families originally described in the Goodship et al mapping study
(ATR-Seckel syndrome; ATR-SS).27 This mutation caused aberrant
splicing of ATR profoundly decreasing ATR expression and disrupt-
ing ATR-dependent DNA damage signaling.27 Crucially, it was also
shown that this mutation was hypomorphic which was important
since it was known that complete knockout of ATR in mice resulted
in early embryonic lethality. ATR-SS cells have proved a very useful
model tool to study the cellular consequences of a clinically rele-
vant deficiency in ATR-function. ATR-SS cells were found to ex-
hibit increased sensitivity to DNA replication fork stalling ('nuclear
fragmentation'), increased replication fork instability, defective G2-
M arrest specifically following UV-irradiation and supernumerary
25
Disorder Gene Microcephaly Growth delay Immunity Cancer
Ataxia
telangiectasia
ATM No Mild, post-natally. Linked
to feeding difficulties
Reduced IgA & IgG4.
Impaired lymphocyte
proliferation. Ig and TCR
loci re-arrangements
Non-Hodgkin's B cell











Mapping study Locus identified Causative gene identified
Goodship et al 3q22.1-q24 ATR
Am J Hum Genet, 2000
Borglum et al 18p11.31-q11.2 Not yet identified
Europ J Hum Genet, 2001
Fairve et al Ruled out mapping to chromosomes
Am J Med Genet 2002 3 and 18 thus implying other loci/locus. None identified
Kilinic et al 14q23 Not yet identified
Europ J Hum Genet, 2003 (Also found some patients mapping to 3q)
Griffith et al 21q22.3 PCNT
Nat Genet, 2008
Table 2.
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centrosomes following treatment with nocodazole in a subset of
mitotic cells.28 This latter phenotype is particularly interesting since
centrosome function is known to be essential for normal brain de-
velopment by mediating a correct balance between symmetric and
asymmetric division in the neuroepithelial stem cell layer. Severe
microcephaly, a clinical term denoting reduced head circumference,
reflects an underlying reduction in brain volume. Whilst microcephaly
has multiple aetiologies, both genetic (syndromic) and environmental
(e.g. perinatal asphyxia, intrauterine infection) it appears particularly
severe in and indeed is a prerequisite diagnostic feature of Seckel
syndrome.29,30
Recently, several distinct mutations in Pericentrin/Kendrin (PCNT),
a gene encoding a large protein that plays a structural role in
centrosomes, have been identified in several Seckel syndrome fami-
lies (PCNT-Seckel syndrome; PCNT-SS) (26). PCNT-SS cells showed
impaired centrosomal localization of PCNT although interestingly
several other centrosomal components investigated localized nor-
mally (e.g. centrin, ninen). Interestingly, PCNT-SS cells also exhibit
impaired ATR-pathway function including defective G2-M check
point activation and also nocodazole-induced supernumerary mitotic
centrosomes.26 This exciting discovery provides the first example
of a defect in a structural centrosomal protein impacting on the DNA
damage response (DDR) and also for such a defect being associated
with a human disorder. Many important events of the cell cycle and
DDR originate from the centrosome. For example, the mitotic pro-
moting factor Cdk1-cyclin B is activated initially at the centrosome
and Chk1 localisation at the centrosome has been shown to be im-
portant for its ability to arrest cells following DNA damage.31,32
How PCNT impacts specifically on ATR-pathway function and not
the ATM-pathway remains unclear. Nevertheless, the identification
of a defect in a core structural centrosomal protein impacting upon
the DDR suggests that defects in other centrosomal components or
centrosomally associated proteins could also adversely impact on the
DDR. In support of this a recent study has indicated that Cep164,
centrosomal protein of unknown function, is required for the mainte-
nance of genomic stability via an MDC1, RPA and a Chk1-dependent
mechanism.33
Mutations in PCNT have subsequently been found in the primor-
dial dwarfism disorder Microcephalic Osteodysplastic Primordial
Dwarfism type II (MOPDii).34 Whilst MOPDii is superficially clini-
cally similar to Seckel syndrome, they are commonly regarded by
clinical geneticists as being distinct disorders, thereby implying that
they have distinct underlying aetiologies. The principal clinically ap-
parent distinctions between MOPDii and Seckel syndrome appear to
be the degree of skeletal involvement (i.e. greater in MOPDii com-
pared to Seckel syndrome), the disproportionate shortness of the
forearms and legs in MOPDii and not Seckel syndrome and the fact
that microcephaly in MOPDii compared to body size appears to be
progressive post-natally, again unlike Seckel syndrome.35 Nevertheless,
MOPDii and PCNT-SS are allelic and PCNT-SS cell lines exhibit
and PCNT siRNA knockdown results in compromised ATR-dependent
checkpoint activation.26 Whether, Seckel syndrome and MOPDii are
distinct disorders or variants of the same underlying genetic defect
remains to be unequivocally demonstrated. Nevertheless, there is
precedent for clinically defined skeletal disorders subsequently being
found to share a common genetic aetiology. Achondrogenesis type B,
Diastrophic Dysplasia, Atelosteogenesis 2 and Multiple Epiphyseal
Dysplasia are all caused by distinct mutations in the DTDST
(Diastrophic Dysplasia Sulphate Transporter) sulphate transporter
gene.36 This issue is discussed in more detail in a recent review by
Kerzendorfer and O'Driscoll (DNA Repair 2009, In Press).
The link between ATR function and clinical pheno-
type
Considering the functional overlap between ATM and ATR, an
obvious question is why does deficiency of ATR-pathway function
result in such a disorder as Seckel syndrome which exhibits major
clinical distinctions to that of A-T? Recent work on a conditional
knockout murine model for ATR has provided some important leads.
Ruzankina and colleagues cleverly circumvented the problem of early
embryonic lethality by conditionally eliminating ATR expression in
the adult mouse.37 Whilst complete loss of ATR in any tissue was not
actually achieved using this approach, the mosaic ATR knockdown
animal (i.e. some wild type ATR gene was retained) yielded severe
phenotypes suggestive of a fundamental role for ATR in the preser-
vation of tissue homesostasis and stem cell integrity. Interestingly,
no increased incidence of malignancy was seen in this model. Acute
cellular loss was seen in rapidly dividing tissues such as the thymus
and not in non-dividing tissues in the adult such as the brain. This
finding is consistent with the known role for ATR in maintaining
replication fork stability.38 The human brain develops from a swel-
ling at the rostral end of the neural tube involving a very rapid and
sustained cellular proliferation from a limited set of stem cells to
generate the cerebral cortex. The normal brain phenotype seen in this
murine model strongly suggests that the microcephalic phenotype
caused by impaired ATR function in Seckel syndrome has an embry-
onic origin. 30,37,39
Interestingly, similar to Seckel syndrome, the skeletal system also
appeared to be profoundly affected in this model as ATR knockdown
resulted in the development of osteoporosis (loss of bone mass)
and kyphosis (curvature of the spine).37 Formation and mainte-
nance of most skeletal elements involves a highly complex process
of endochondral ossification wherein a cartilagenous template is
converted into calcified bone.40 A key feature of bone growth is the
coordination of chrondrogenesis and osteogenesis. The cartilage tem-
plate is formed by chondrocytes transiting through maturational stages
of proliferation followed by cell cycle exit (hypertrophic phase) within
the epiphyseal growth plates. Hypertrophic chondrocytes ultimately
die by apoptosis and are replaced by trabecular bone mediated by
osteoblast mineralisation. Again, ATR-mediated stem and progeni-
tor cell attrition would be predicted to adversely affect the homeo-
stasis of this tissue.
As mentioned earlier, targeted knockout of ATR in mice resulted
in very early lethality during development, prior to gastrulation,
26
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associated with massive embryonic apoptosis.16 Unfortunately, this
early embryonic lethality rendered the amount of functional informa-
tion obtainable from this approach somewhat limited. One interest-
ing observation from these studies was that the heterozygote (ATR+ /–)
animals were not born at expected Mendelian frequency.16 This sug-
gested that a diploid complement of ATR was required for normal
development. Evidence for an impact of ATR haploinsufficiency in
humans is illustrated by a group of conditions referred to as Genomic
Disorders.
Gene copy number variation, Genomic Disorders and
ATR
Gene copy number variation (CNV) appears to be a common ge-
netic trait in clinically unaffected or 'normal' individuals highlighting
the plasticity of the human genome.41 Nevertheless, an expanding list
of human conditions known as Genomic Disorders exit represent-
ing a clinically diverse group of disorders caused by gain, loss or
re-orientation (e.g. inversions) of a genomic region containing dos-
age-sensitive genes.42 One class of Genomic Disorder is caused by
hemizygous deletions resulting in haploinsufficiency of a single or,
more usually, several genes. For example, DiGeorge syndrome is
caused by a heterozygous contiguous gene deletion of 1.5-3MBp on
chromosome 22q11.2 involving up to about 30 genes.43 There is mount-
ing evidence, particularly from mouse studies, that haploinsufficiency
of several genes whose products encode players in either DNA dam-
age signalling, repair and cell cycle checkpoint activation adversely
impacts the normal response to DNA damage and consequently, upon
genomic stability (Reviewed in Kerzendorfer and O'Driscoll DNA
Repair 2009 In Press). Recently, defective ATR-pathway function
has been described in a group of distinct Genomic Disorders in-
volving haploinsufficiency of ATR itself or ATR-pathway compo-
nents (RPA1, RFC2) (Table 3).44 The clinical spectrum of these
Genomic Disorders includes microcephaly and growth retardation
which may indicate that defective ATR-pathway could be a contrib-
uting factor to these conditions.
Monogenic human disorders exhibiting impaired
ATR-pathway function
Impaired ATR-pathway function appears to be a feature of cell
lines from patients with several distinct DDR-defective conditions.
Whilst these disorders are all characterised by a distinct set of clini-
cal features there is significant clinical overlap with Seckel syndrome,
particularly concerning the developmental abnormalities such as
microcephaly and growth retardation.
MCPH1-dependent Primary Microcephaly
Autosomal recessive Primary Microcephaly, a disorder characterised
by the presence of a severe microcephaly in the absence of other
overt clinical features, is a genetically heterogeneous condition. To
date, mutations in four genes, all of which encode centrosomal pro-
teins, have been described for this disorder (MCPH1, ASPM,
CDK5/RAP2, CENPJ).45 Microcephalin (MCPH1), the first Primary
Microcephaly gene identified encodes a BRCT-containing product
that has been implicated in the response to DSB's.46,47 Interestingly,
MCPH1-patient derived cell lines phenocopy those of ATR-SS and
are defective in ATR-dependent checkpoint activation and also ex-
hibit supernumerary mitotic centrosomes.48 Furthermore, MCPH1
was found to interact with Chk1, a substrate and downstream effector
of ATR.48
Nijmegen breakage syndrome
Nijmegen breakage syndrome (NBS) is caused by hypomorphic
mutations in the Nbs1 component of the MRN complex.49 Historically,
NBS has been described as an 'A-T-like' disorder as cell lines from
both conditions exhibit clinical and cellular radio-sensitivity, cell cycle
checkpoint defects in response to DSB's and similar forms of ge-
netic instability (i.e. chromosome 7-14 translocations).50 But, NBS1
is also an ATR substrate and NBS patients exhibit microcephlay and
growth retardation, clinical features associated with Seckel syndrome
and not A-T. Similar to MCPH1, NBS patient-derived cell lines have
also been shown to be compromised for ATR-dependent checkpoint
activation and other aspects of ATR-pathway function. 38 Hence, NBS
represents a human disorder that exhibits defects in elements of both
ATM and ATR-pathway activity and whose clinical features likely
represent a compendium of these defects.
Fanconi anaemia
Fanconi anaemia (FA), is a genetically heterogeneous condition
characterised by a progressive aplastic anaemia, skeletal abnormali-
ties, microcephaly and lymphoid malignancy. FA is caused by mu-
tations in different genes whose products co-ordinately function in
the cellular response to DNA cross-links.51 Several of these genes
encode products that together mediate the monoubiquitination and
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activation of the FANC-D2 protein in response to DNA damage.
ATR and NBS1 have been shown to be required for this specific
modification. In fact, ATR-SS and NBS patient-derived cell lines fail
to monoubiquitylate FANC-D2 following treatment with replication
fork inhibitors.38 FANCD2 has been shown to be phosphorylated by
ATM and ATR further highlighting the over-lap between these DDR
pathways.52
Xeroderma Pigmentosum (Complementation group
A; XP-A)
Xeroderma Pigmentosum (XP) is a genetically heterogeneous con-
dition caused by mutations in various components of the nucleotide
excision repair pathway (NER), a complex multifactorial DNA re-
pair pathway which detects and excises 'bulky' or helix-distorting
lesions (e.g UV-photoproducts) from DNA. Cells from XP patients
are characterised by dramatic UV-sensitivity and increased UV-
induced mutagenesis. The primary clinical manifestation of XP is
a >1000 fold predisposition to basal cell carcinoma of the skin, spe-
cifically on sun exposed areas of the body.53 Progressive neurological
degeneration is also frequently seen in XP although its course is highly
variable. This manifests clinically as abnormal gait, sensorineural
deafness and the lack of deep tendon reflexes. Structural neurologi-
cal abnormalities such as microcephaly, cerebellar atrophy and en-
larged ventricles are also apparent in some XP complementation
groups, particularly in XP-A.54 Endogenously generated DNA dam-
age is implicated in the progression of neurological impairment in
this disorder. It has been postulated that reactive oxygen-induced
DNA lesions such as cyclo-deoxyadenine and/or cyclo-deoxyguanine
may accumulate in neurons of XP patients leading to progressive
degeneration.55
Interestingly, primary fibroblasts derived from XP-A patients
fail to undergo ATR-dependent ã-H2AX formation following UV-
irradiation.27 XP-A cells do not excise UV-photoproducts from their
DNA. Since single stranded DNA, an intermediate generated during
normal NER, is required for ATR activation, it is likely that the fail-
ure to excise UV-photoproducts from the DNA of XP-A results in
the consequent failure to activate ATR appropriately. Furthermore,
XP-A cells also appear to be defective in the ATR-dependent G2-M
cell cycle checkpoint following UV-irradiation.56 Hence XP-A is
characterised by a DNA repair and specific (ATR-dependent) cell
cycle defect. It is unclear to what extent, if any, compromised ATR-
function could influence the clinical phenotype of XP-A. Although,
it is worth noting that microcephaly is a prominent feature this XP
complementation group.
Mosaic Varigated Aneuploidy
The mitotic spindle assembly checkpoint (SAC) is a highly com-
plex ordered process that functions to delay the onset of anaphase
until all chromosomes are aligned correctly on the metaphase plate
thus ensuring accurate segregation of chromosomes into daughter
cells.57 Mosaic Varigated Aneuploidy (MVA) is a congenital disor-
der of SAC dysfunction.58 MVA is an autosomal recessive condition
characterised by intra-uterine and post-natal growth retardation,
microcephaly and an increased frequency of childhood tumours in-
cluding leukaemia, Wilms' tumour and rhabdomysarcoma. Some of
these clinical features are reminiscent of Seckel syndrome (ATR-SS,
PCNT-SS). To date, mutations in BUB1B, which encodes the SAC
kinase BubR1, remain the sole genetic defect described in this con-
dition.59,60 Cells from patients with BUB1B mutations are insensitive
to mitotic arrest induced by SAC activators such as colcimed. All
MVA patient-derived lines typically exhibits mosaic or variable
aneuploidies involving different chromosomes, mainly trisomies and
monosomies, and premature chromatid separations (PCS) consistent
with defective SAC. There is increasing evidence of overlap and
communication between the SAC and DDR-mediated cell cycle
checkpoint machinery. BubR1+/ – mouse embryonic fibroblasts were
found to exhibit reduced DNA damage-induced ã-H2AX formation
and defective G2/M checkpoint arrest.61 Furthermore, Chk1, an effector
of ATR, has recently been shown to play a role in the SAC by in-
fluencing optimal activation of Aurora-B and BubR1 kinase activi-
ties.62 Whilst a primary defect in ATR-pathway function has not been
specifically demonstrated in MVA, the above findings would suggest
that it could be a possibility. Furthermore, a phenotypic and func-
tional comparison between MVA and PCNT-mutated MOPDii has
been made.34
In conclusion
ATR and ATM play pivotal roles in orchestrating the cellular re-
sponse to DNA damage. Congenital defects in ATR-pathway func-
tion are associated with Seckel syndrome in humans. Genetic evi-
dence suggests that further novel Seckel syndrome causative genes
await identification. Evidence derived from Seckel syndrome patient
cell lines suggests that these novel genetic defects are likely to im-
pair ATR-pathway function. The ATR-pathway appears to be sen-
sitive to haploinsufficieny and several Genomic Disorders that are
genetically haploinsufficient for ATR or specific pathway components
(e.g. RPA1, RFC2) exhibit defective ATR-function at the cellular
level. Furthermore, compromised ATR-pathway function is also a
feature of several other DDR-defective conditions, all of which bear
some clinical similarity to Seckel syndrome. It is hoped that work
using this material coupled with conditional ATR knockdown sys-
tems, perhaps even tissue-specific systems, will provide further in-
sight into the mechanisms underlying the cellular and organismal
consequences of compromised ATR-pathway function. This should
facilitate a greater understanding of why defective ATR-function in
humans results in a disorder that is clinically distinct to that of defec-
tive ATM (i.e. Ataxia Telangiectasia), perhaps highlighting a hith-
erto under-appreciated functional link between cell cycle or DNA
damage response pathway components and those of tissue-specific
developmental pathways.
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